Summit Therapeutics (SMMT) Q3 2024 earnings summary

Executive summary

• Ivonescimab achieved a 49% reduction in disease progression or death versus pembrolizumab in Phase III trials for NSCLC, with benefit across PD-L1 and histology subgroups and encouraging Phase II data in multiple tumor types.

• Enrollment completed in the global Phase III HARMONI trial for EGFR-mutated advanced NSCLC; topline data expected mid-2025; FDA Fast Track Designation received.

• HARMONI-3 trial expanded to include non-squamous NSCLC and updated endpoints to PFS and OS; HARMONI-7 trial to initiate early 2025.

• $235 million raised in private placement in September 2024, boosting cash reserves and supporting clinical expansion.

• Strategic alliances formed, including with MD Anderson Cancer Center, and expanded licensing to new territories.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $487 million at September 30, 2024, up from $186.2 million at year-end 2023.

• Q3 2024 GAAP R&D expenses were $37.7 million; non-GAAP R&D expenses were $31.9 million.

• Q3 2024 GAAP G&A expenses were $20.4 million; non-GAAP G&A expenses were $6.8 million.

• Q3 2024 GAAP operating expenses: $58.1 million; non-GAAP: $38.7 million.

• Q3 2024 GAAP net loss: $56.3 million ($0.08/share); non-GAAP net loss: $36.9 million ($0.05/share).

Outlook and guidance

• Sufficient liquidity to fund planned and expanded ivonescimab trials into 2025.

• Topline data from the global HARMONI Phase III trial expected mid-2025; HARMONI-7 trial initiation planned for early 2025.

• HARMONI-3 trial expansion to include non-squamous NSCLC and increased sample size.

• Continued expansion of ivonescimab clinical development into additional solid tumor indications based on positive Phase II data.